Abstract
A shortage of the drug methylprednisolone to support “business as usual” has led to organisations being asked to stop prescribing it for the treatment of acute respiratory distress syndrome (ARDS) in patients with COVID-19. A supply disruption alert from the Department of Health and Social Care (DHSC) and NHS England and NHS Improvement, released on 14 January […]
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
